Graves’ disease treatment improves quality of life, but not in the same way across domains
Graves’ disease does more than drive biochemical hyperthyroidism. It disrupts sleep, energy, mood, social functioning, body image, and sexual well-being, and those symptoms can persist long after thyroid hormone levels improve. A systematic review and meta-analysis published in Scientific Reports compared quality-of-life outcomes after three common treatment paths: antithyroid drugs (ATD), radioiodine (RAI), and surgery.
Sixteen studies met inclusion criteria, and the analysis pooled scores from generic and thyroid-specific patient-reported outcome tools. The central finding was straightforward: all three therapies were associated with better quality of life, but the pattern of recovery differed by domain and by treatment. Physical functioning tended to score well after ATD and RAI, while social functioning reached its highest level after surgery. Even so, no treatment erased the burden entirely, and fatigue remained the most persistent complaint across all three approaches.
Fatigue stayed low no matter which therapy patients received
The most consistent signal across the review was tiredness. In the ThyPRO instrument, tiredness was the worst-scoring domain after ATD, surgery, and RAI alike. The reported scores were 40.04 for ATD, 32.50 for surgery, and 41.90 for RAI, each on its own study-specific scale as pooled in the analysis. This is clinically important because persistent fatigue in Graves’ disease often outlives the initial endocrine correction and can reflect a mixture of residual hormonal fluctuation, autoimmune activity, sleep disruption, mood symptoms, and the recovery burden after definitive therapy.
Physical functioning looked relatively stronger than other domains. Among SF-36 measures, the highest physical functioning score appeared after RAI at 84.02, with ATD at 66.24. Those numbers suggest that once thyroid excess is controlled, many patients regain enough physical capacity to resume ordinary daily activity. Yet the same data set shows that physical recovery does not necessarily translate into emotional relief or complete symptom resolution.
Surgery and radioiodine split the benefit profile across symptom clusters
The strongest domain-level gains were not uniform. Surgery produced the best social functioning score, 72.32, which may reflect the appeal of rapid, definitive disease control for patients whose daily lives have been dominated by fluctuating symptoms, repeated monitoring, or treatment uncertainty. Surgery also delivered the lowest bodily pain score on SF-36, at 51.11, although the wide confidence interval signals considerable variability across studies.
RAI and surgery both performed well for goiter symptoms in ThyPRO, with surgery reaching 7.08 and RAI 12.03. In endocrine practice, compressive or visible goiter symptoms often weigh heavily on patient perception, especially when neck enlargement affects swallowing, breathing, clothing choices, or self-image. A treatment that rapidly reduces thyroid volume can therefore improve quality of life through a mechanism that is partly mechanical and partly psychological.
Sex life told a different story. ATD produced the most favorable sex life score at 11.59, and it outperformed RAI in the direct comparison reported in the meta-analysis. That finding likely reflects the balance between symptom control and preservation of thyroid function without the abrupt transition to hypothyroidism that can follow definitive therapy. Sexual well-being in thyroid disease is sensitive to energy level, mood, weight change, and endocrine stability, so even modest differences in treatment trajectory may become visible to patients long before they appear in laboratory data.
Emotional recovery favored surgery over radioiodine in specific comparisons
Direct comparisons between therapies showed a few clear divergences. Surgery delivered significantly better quality-of-life scores than RAI for depression and emotional susceptibility. Those outcomes fit a plausible clinical pattern: when a patient feels the disease has been definitively removed, the psychological burden of relapse surveillance and prolonged symptom uncertainty may ease. RAI can be highly effective, but it often unfolds more gradually, and some patients move through a period of biochemical instability before reaching a stable state.
This matters because Graves’ disease is not simply a thyroid hormone disorder. It is an autoimmune illness with visible and invisible consequences, and patients often judge treatment by how quickly they can reclaim ordinary emotional and social functioning. Laboratory normalization is necessary, but it is not enough to predict how a patient feels at work, in relationships, or in everyday life.
Why patient-reported outcomes should shape Graves’ disease counseling
The review used PRISMA methods and drew on PubMed, Embase, Scopus, and Web of Science through July 30, 2025. Quality-of-life measurement relied on SF-36 and ThyPRO, two tools that capture different dimensions of disease burden. SF-36 offers a broad view of general health status, while ThyPRO is designed specifically for thyroid disorders and is more likely to detect the symptoms that patients actually notice in clinic.
For clinicians, the practical message is not that one therapy is universally superior. It is that each option shifts the quality-of-life profile in a different direction. ATD may preserve sex life better than RAI in some patients. Surgery may improve emotional and social recovery more strongly than RAI. RAI can deliver strong physical functioning scores and favorable goiter-related outcomes, but fatigue remains stubborn across the board.
What this meta-analysis can and cannot settle
The pooled estimates came from only 16 studies, and the analysis combined different questionnaires, follow-up intervals, and study designs. Those features limit how precisely the numbers can be compared across treatment groups. The confidence intervals around some domains were wide enough to show that the underlying evidence remains uneven, especially for pain and other subjective symptoms.
Still, the pattern is clinically useful. Graves’ disease treatment should not be discussed only as a decision between euthyroidism, hypothyroidism, or recurrence risk. Patients also want to know which path is most likely to leave them less exhausted, more socially engaged, emotionally steadier, and able to return to a normal life. This review gives endocrinologists a structured way to frame that conversation, while also showing that tiredness remains the most durable symptom across all three treatment strategies.